Peripheral intravascular lithotripsy for transcatheter aortic valve implantation: a multicentre observational study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

  • Giulia Nardi
  • De Backer, Ole
  • Francesco Saia
  • Søndergaard, Lars
  • Francesca Ristalli
  • Francesco Meucci
  • Miroslava Stolcova
  • Alessio Mattesini
  • Pierluigi Demola
  • Xi Wang
  • Anees Al Jabri
  • Tullio Palmerini
  • Antonio Giulio Bruno
  • Alfonso Ielasi
  • Eric Van Belle
  • Sergio Berti
  • Carlo Di Mario

Background: The presence of severe calcific atherosclerosis at the iliofemoral axis may preclude transcatheter aortic valve implantation (TAVI) by the transfemoral (TF) approach. Intravascular lithotripsy (IVL) is a novel technology that fractures intimal/medial calcium and increases vessel compliance allowing TF TAVI in selected patients with peripheral artery disease (PAD). Aims: The aim of this study was to report on the safety and efficacy of IVL-assisted TF TAVI in an all-comers population. Methods: Clinical, imaging and procedural data on all consecutive patients treated by IVL-assisted TF TAVI in six high-volume European centres (2018-2020) were collected in this prospective, real-world, multicentre registry. Results: IVL-assisted TF TAVI was performed in 108 patients, increasing from 2.4% to 6.5% of all TAVI from 2018 to 2020, respectively. The target lesion was most often localised at the common and/or external iliac artery (93.5% of cases; average TL-MLD 4.6±0.9 mm with 318 degrees of calcium arc). Transfemoral aortic valve delivery was successful in 100% of cases; final procedural success in 98.2% (two conversions to cardiac open surgery for annular rupture and valve migration). Complications of the IVL-treated segments consisted of 1 perforation and 3 major dissections requiring stent implantation (2 covered stents and 2 BMS). Access-site-related complications included 3 major bleedings. Three in-hospital deaths were recorded (2.8%, 1 failed surgical conversion after annular rupture, 1 cardiac arrest after initial valvuloplasty, 1 late hyperkalaemia in renal dysfunction). Conclusions: IVL-assisted TF TAVI proved to be a safe and effective approach, which helps to expand the indications for TF TAVI in patients with severe calcific PAD. However, these patients continue to have a higher-than-average incidence of periprocedural complications.

OriginalsprogEngelsk
TidsskriftEuroIntervention
Vol/bind17
Udgave nummer17
Sider (fra-til)E1397-E1406
Antal sider7
ISSN1774-024X
DOI
StatusUdgivet - 2022

Bibliografisk note

Funding Information:
O. De Backer has received institutional research grants and consulting fees from Abbott, Boston Scientific and Shockwave Medical Inc. O. De Backer has received speaker fees from Shockwave Medical. F. Saia is a member of the Advisory Board for Edwards, Medtronic, Abbott, Bayer, Biotronik, Amgen, Boehringer-Ingel-heim, and AstraZeneca, and has received lecture fees from Edwards, Medtronic, Abbott, Bayer, Amgen, Boehringer-Ingelheim, Astra-Zeneca, Boston Scientific, Volcano, and Chiesi, outside the submitted work. F. Meucci reports receiving speaker and consultation fees from Medtronic, Edwards and Boston Scientific. T. Palmerini has received lecture fees from Biotronik and Edwards. C. Di Mario has received research or educational grants from Abbott, Amgen, Asahi Intecc, AstraZeneca, Boston Scientific, Cardinal Health, CSL Behring, Chiesi, Daiichi Sankyo, Edwards, Medtronic, Menarini, Pfizer, Sanofi, Shockwave, Teleflex, and Volcano/Philips. The other authors have no conflicts of interest to declare. The Guest Editor reports lecture fees paid to his institution from Amgen, Bayer Healthcare, Biotronik, Boehringer Ingelheim, Boston Scientific, Daiichi Sankyo, Edwards Lifesciences, Ferrer, Pfizer, and Novartis, consultancy fees paid to his institution from Boehringer Ingelheim, and grant support from Bayer Healthcare, Boston Scientific, Biotronik, Edwards Lifesciences, GlaxoSmithKline, Medtronic, and Pfizer.

Publisher Copyright:
© Europa Digital & Publishing 2022. All rights reserved. SU

ID: 313772002